Less Is More: The Impact of Deprescribing Psychotropic Drugs on Behavioral and Psychological Symptoms and Daily Functioning in Nursing Home Patients. Results From the Cluster-Randomized Controlled COSMOS Trial
Marie H Gedde, Bettina S Husebo, Janne Mannseth, Reidun L S Kjome, Mala Naik, Line I Berge, Marie H Gedde, Bettina S Husebo, Janne Mannseth, Reidun L S Kjome, Mala Naik, Line I Berge
Abstract
Objective: To investigate the impact of medication reviews using collegial mentoring and systematic clinical evaluation on psychotropic prescriptions, behavioral and psychological symptoms of dementia (BPSD), and activities of daily living (ADL).
Design: Four-month multicenter, multicomponent, cluster-randomized, single-blinded controlled trial.
Setting: Thirty-three Norwegian nursing homes including 67 nursing home wards (clusters).
Participants: A total of 723 enrolled patients, of which 428 participated in the study; 217 were randomized to the intervention and 211 to care as usual (control).
Intervention: The COSMOS intervention consisted of Communication, Systematic pain management, Medication reviews, Organization of activities, and Safety. During medication review, the nursing home physician evaluated treatment with colleagues systematically using the results from validated clinical assessments.
Measurements: Mean changes from baseline to month 4 in the number of prescribed psychotropic drugs (antipsychotics, anxiolytics, hypnotics or sedatives, antidepressants, and antidementia drugs); Neuropsychiatric Inventory Nursing Home Version (NPI-NH) and Cornell Scale of Depression in Dementia (CSDD); Lawton and Brody's Physical Self Maintenance Scale (PSMS).
Results: Compared to control, the mean change in prescribed psychotropic drugs was reduced both in total and regular number, while mean changes in NPI-NH and CSDD scores did not differ between the groups. Mean change in PSMS showed improvement in the intervention group, and deterioration in the control group.
Conclusion: Medication reviews using collegial mentoring and systematic clinical evaluation led to safe deprescribing, as the reductions in psychotropic drug use did not negatively affect BPSD, while ADL improved.
Trial registration: ClinicalTrials.gov NCT02238652.
Keywords: Deprescribing; activities of daily living (ADL); behavioral and psychological symptoms of dementia (BPSD); dementia; medication review; neuropsychiatric symptoms (NPS); nursing homes; psychotropic drugs.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Source: PubMed